The National Cancer Institute (NCI) IMAT Program offers this grant for the advanced development and validation of emerging molecular and cellular analysis technologies. This grant is for projects demonstrating initial feasibility, requiring further rigorous refinement for broader adoption in cancer research. It targets technologies offering novel capabilities to probe cancer biology, aiming to accelerate research in areas like early detection, diagnosis, treatment, and health disparities. Funding prioritizes technological innovation improving cancer characterization, not new applications of existing methods.
Opportunity ID: 336710
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | RFA-CA-22-002 |
Funding Opportunity Title: | Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Education Health |
Category Explanation: | – |
Expected Number of Awards: | – |
Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Nov 24, 2021 |
Last Updated Date: | Nov 24, 2021 |
Original Closing Date for Applications: | Sep 22, 2022 |
Current Closing Date for Applications: | Sep 22, 2022 |
Archive Date: | Oct 28, 2022 |
Estimated Total Program Funding: | – |
Award Ceiling: | $300,000 |
Award Floor: | – |
Eligibility
Eligible Applicants: | Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses County governments Public housing authorities/Indian housing authorities Small businesses Independent school districts Others (see text field entitled “Additional Information on Eligibility” for clarification) Special district governments Private institutions of higher education State governments City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) |
Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
Agency Name: | National Institutes of Health |
Description: | This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. |
Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-002.html |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Related Documents
Folder 336710 Full Announcement-RFA-CA-22-002 -> RFA-CA-22-002-Full-Announcement.pdf
Packages
Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
FORMS-G | Use for due dates on or after January 25, 2022 | PKG00270639 | Mar 22, 2022 | Sep 22, 2022 | View |
Package 1
Mandatory forms
336710 RR_SF424_5_0-5.0.pdf
336710 PHS398_CoverPageSupplement_5_0-5.0.pdf
336710 RR_OtherProjectInfo_1_4-1.4.pdf
336710 PerformanceSite_4_0-4.0.pdf
336710 RR_KeyPersonExpanded_4_0-4.0.pdf
336710 RR_Budget_3_0-3.0.pdf
336710 PHS398_ResearchPlan_4_0-4.0.pdf
336710 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
336710 RR_SubawardBudget30_3_0-3.0.pdf
336710 PHS_AssignmentRequestForm_3_0-3.0.pdf